Katharina Schindowski

List of Publications by Year
in descending order

41	2,202	279798	302126
papers	citations	23 h-index	39 g-index

46	46	46	3240
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Editorial: Intranasal Drug Delivery: Challenges and Opportunities. Frontiers in Pharmacology, 2022, 13, 868986.	3.5	7
2	Hyaluronate Spreading Validates Mucin-Agarose Analogs as Test Systems to Replace Porcine Nasal Mucosa Explants â€“ an Experimental and Theoretical Investigation. Colloids and Surfaces B: Biointerfaces, 2022, , 112689.	5.0	0
3	Nano-in-Micro-Particles Consisting of PLGA Nanoparticles Embedded in Chitosan Microparticles via Spray-Drying Enhances Their Uptake in the Olfactory Mucosa. Frontiers in Pharmacology, 2021, 12, 732954.	3.5	13
4	Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration. Antibodies, 2021, 10, 47.	2.5	8
5	Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa. Pharmaceutics, 2021, 13, 1904.	4.5	16
6	Establishment of an Olfactory Region-specific Intranasal Delivery Technique in Mice to Target the Central Nervous System. Frontiers in Pharmacology, 2021, 12, 789780.	3.5	9
7	Impact of Glycosylation and Species Origin on the Uptake and Permeation of IgGs through the Nasal Airway Mucosa. Pharmaceutics, 2020, 12, 1014.	4.5	12
8	Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650. Pharmaceutics, 2019, 11, 367.	4.5	43
9	Efficient Construction and Effective Screening of Synthetic Domain Antibody Libraries. Methods and Protocols, 2019, 2, 17.	2.0	12
10	Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?. Pharmaceutics, 2018, 10, 107.	4.5	21
11	Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics, 2018, 10, 116.	4.5	242
12	Regulation of Neurotrophic Factors During Pathogenic Tau-Aggregation: A Detailed Protocol for Double-Labeling mRNA by In Situ Hybridization and Protein Epitopes by Immunohistochemistry. Methods in Molecular Biology, 2017, 1523, 391-414.	0.9	1
13	A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. International Journal of Pharmaceutics, 2017, 532, 537-546.	5.2	50
14	Data of rational process optimization for the production of a full IgG and its Fab fragment from hybridoma cells. Data in Brief, 2016, 8, 426-435.	1.0	5
15	First Steps to Develop and Validate a CFPD Model in Order to Support the Design of Nose-to-Brain Delivered Biopharmaceuticals. Pharmaceutical Research, 2016, 33, 1337-1350.	3.5	21
16	Protein aerosol for intranasal nose to brain (N2B) delivery. BMC Proceedings, 2015, 9, .	1.6	2
17	Nose-to-Brain delivery of insulin for Alzheimerâ€™s disease. ADMET and DMPK, 2015, 3, .	2.1	23
18	Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 121.	1.3	1

#	Article	IF	Citations
19	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. Immunity and Ageing, 2013, 10, 18.	4.2	97
20	Optimized fermentation conditions for improved antibody yield in hybridoma cells. BMC Proceedings, 2013, 7, .	1.6	2
21	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Frontiers in Aging Neuroscience, 2013, 5, 25.	3.4	12
22	Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with tau Pathology?. Current Alzheimer Research, 2011, 8, 633-638.	1.4	38
23	Regulation of GDF-15, a distant TGF-Î² superfamily member, in a mouse model of cerebral ischemia. Cell and Tissue Research, 2011, 343, 399-409.	2.9	53
24	Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease. Current Alzheimer Research, 2009, 6, 152-157.	1.4	50
25	Expression of trkB and trkC receptors and their ligands brainâ€derived neurotrophic factor and neurotrophinâ€3 in the murine amygdala. Journal of Neuroscience Research, 2008, 86, 411-421.	2.9	20
26	Neurogenesis and cell cycleâ€reactivated neuronal death during pathogenic tau aggregation. Genes, Brain and Behavior, 2008, 7, 92-100.	2.2	48
27	Neurotrophic factors in Alzheimerâ€™s disease: role of axonal transport. Genes, Brain and Behavior, 2008, 7, 43-56.	2.2	298
28	Early Axonopathy Preceding Neurofibrillary Tangles in Mutant Tau Transgenic Mice. American Journal of Pathology, 2007, 171, 976-992.	3.8	122
29	Increased T-cell Reactivity and Elevated Levels of CD8+ Memory T-cells in Alzheimerâ€™s Disease-patients and T-cell Hyporeactivity in an Alzheimerâ€™s Disease-mouse Model: Implications for Immunotherapy. NeuroMolecular Medicine, 2007, 9, 340-354.	3.4	42
30	Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits. American Journal of Pathology, 2006, 169, 599-616.	3.8	337
31	Apoptosis of CD4+ T and Natural Killer Cells in Alzheimer's Disease. Pharmacopsychiatry, 2006, 39, 220-228.	3.3	41
32	p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. Journal of Cell Science, 2005, 118, 1291-1298.	2.0	93
33	Enhanced ROS-Generation in Lymphocytes from Alzheimerâ€™s Patients. Pharmacopsychiatry, 2005, 38, 312-315.	3.3	47
34	Enlarged infarct volume and loss of BDNF mRNA induction following brain ischemia in mice lacking FGF-2. Experimental Neurology, 2004, 189, 252-260.	4.1	45
35	Impact of Aging: Sporadic, and Genetic Risk Factors on Vulnerability to Apoptosis in Alzheimer's Disease. NeuroMolecular Medicine, 2003, 4, 161-178.	3.4	30
36	Age-related impairment of human T lymphocytesâ€™ activation: specific differences between CD4+ and CD8+ subsets. Mechanisms of Ageing and Development, 2002, 123, 375-390.	4.6	69

#	Article	IF	Citations
37	Alzheimer's Disease-like Alterations in Peripheral Cells from Presenilin-1 Transgenic Mice. Neurobiology of Disease, 2001, 8, 331-342.	4.4	55
38	Age-related increase of oxidative stress-induced apoptosis in micePrevention by Ginkgo biloba extract (EGb761). Journal of Neural Transmission, 2001, 108, 969-978.	2.8	81
39	Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neuroscience Letters, 2000, 292, 87-90.	2.1	59
40	Age-related changes of apoptotic cell death in human lymphocytes. Neurobiology of Aging, 2000, 21, 661-670.	3.1	66
41	In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system. Cancer Gene Therapy, 1999, 6, 139-146.	4.6	10